Tuesday , October 17 2017
Home / Managing Editor, Diabetes in Control (page 36)

Managing Editor, Diabetes in Control

Managing Editor, Diabetes in Control

Discontinuation of TZD Reduces Fracture Rates

Managing stress

Thiazolidinediones (TZDs), rosiglitazone and pioglitazone, have been shown to increase fracture risk in women after a year of TZD use; however, there has been little data available on the effects of the discontinuation of TZD. This longitudinal observational cohort study used data from an ancillary study of skeletal health within ...

Read More »

Finerenone Improves Albuminuria in Diabetic Nephropathy Patients

blood-glucose-test

Mineralocorticoid receptor antagonists (MRAs) are often used with a renin-angiotensin system (RAS) blocker to further reduce proteinuria in patients with CKD. However, eplerenone and spironolactone increase the risk of hyperkalemia in these patients. Finerenone (BAY94-8862) is a new nonsteroidal MRA that has better receptor selectivity than spironolactone, associating with lower ...

Read More »

Editor’s Note – SE091715

dave

GLP-1 analog therapy hit a new threshold last month with the most prescriptions ever filled in a 30-day period. There are also more prescribers using these products than ever before. I think that one of the reasons is the fear of needles has decreased. I believe that it was not ...

Read More »